Official answer. Flavia Watson is the singer on the Humira commercial “Not always where I need to be” released July 16, 2018.

The drug suppresses the immune system by blocking the activity of TNF. TNF is a protein produced naturally by the body's immune system. Some people with certain autoimmune diseases produce too much TNF. Humira is designed to stop tumor necrosis factor-α, or TNF, from attacking healthy cells.

Humira is the brand name of the original adalimumab medicine. There are now 5 newer versions of adalimumab, known by the brand names Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma. These newer medicines are biosimilars.

As AbbVie moved away from promotional spend on its aging megablockbuster Humira at the same time Sanofi and Regeneron stepped up their TV campaigns for Dupixent in 2021, you might be forgiven for thinking AbbVie was content to no longer top the annual largest TV drug ad spending lists.

Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. These infections include active tuberculosis (TB), reactivation of latent TB, invasive fungal infections, and bacterial, viral and other infections due to opportunistic pathogens.

Humira contains the active drug adalimumab, which is a biologic medication. Biologics are medications made from living cells. Adalimumab belongs to a class of medications known as tumor necrosis factor (TNF) blockers. (A class of medications is a group of drugs that work in a similar way.)

Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002. Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.

Humira brought in more than $20 billion in 2021 for its manufacturer, AbbVie. Although biosimilars like Amgen's Amjevita have been marketed in Europe since 2018, patents and exclusivity laws prevented competition in the U.S. Until now.

A significant factor in Humira's success has been the absence of biosimilar competition. This is partially related to Paragraph IV settlement agreements negotiated between AbbVie and adalimumab biosimilar manufacturers.

THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States . AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.

Cosentyx is taken every 4 weeks, while Humira needs to be taken every 2 weeks. And Cosentyx causes fewer side effects, particularly serious side effects, than Humira. But it's also important to consider your health history. For example, if you have inflammatory bowel disease, taking Cosentyx could make it worse.

Humira (adalimumab) is a medication that is used over the long-term. Your doctor will check your medication at regular intervals to be sure staying on Humira is appropriate for you. Your dose for Humira can also vary and depends on the condition being treated. However, many patients stay on Humira for many years.